newsfilter
← Latest News
GlobeNewswire·

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  • Intellia Therapeutics, Inc. awarded inducement grants to three new employees on November 1, 2026, as a material inducement for employment.
  • The grants consisted of time-based restricted stock units totaling 12,900 shares of common stock, with one-third vesting annually over three years.
  • All equity vesting is contingent upon each employee's continued service through the applicable vesting dates.
  • These awards were granted outside of stockholder-approved equity incentive plans under the company's 2024 Inducement Plan, which was adopted by the board in June 2024.
  • The compensation committee approved the awards in accordance with Nasdaq Listing Rule 5635(c)(4).
  • Intellia Therapeutics is a biopharmaceutical company focused on developing CRISPR-based curative treatments for severe diseases.
Company
Intellia Therapeutics, Inc.
Keywords
Nasdaq:NTLA, Intellia Therapeutics, Inc.